Methods for the prevention and treatment of hearing loss

The use of Zorifertinib and AZD compounds addresses the lack of effective treatments for hearing loss by inhibiting EGFR signaling and protecting ear cells from noise and ototoxicity, effectively preventing hearing loss and improving auditory function.

WO2024215467A9PCT designated stage expired Publication Date: 2024-12-05TING THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/021326
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-28
Filing Date
2024-03-25
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for hearing loss, particularly noise-induced and ototoxicity-related hearing loss, lack effective medications for prevention and treatment, with existing remedies like hearing aids only amplifying sound and not restoring normal hearing or addressing the underlying issue.

Method used

Administration of a pharmaceutical composition containing Zorifertinib or its pharmaceutically acceptable salts, combined with AZD 5438 or AZD 3759, which act as EGFR and CDK2 inhibitors, to protect ear cells from death caused by noise and ototoxic events, such as drug treatments, by inhibiting excitotoxicity and attenuating EGFR signaling pathways.

Benefits of technology

The combination of Zorifertinib and AZD compounds effectively protects inner ear hair cells from noise-induced damage and ototoxicity, reducing permanent threshold shifts and preserving cochlear synapses, thereby preventing hearing loss and improving auditory function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024021326_05122024_PF_FP_ABST
    Figure US2024021326_05122024_PF_FP_ABST
Patent Text Reader

Abstract

In one aspect, use of Zorifertinib as an active agent to treat hearing loss and to prevent hearing loss, and methods of treating and / or preventing hearing loss or disorders using the compositions are disclosed. Administered orally, Zorifertinib was successfully detected in the perilymph fluid of the inner ear in mice with favorable pharmacokinetic attributes. Zorifertinib, in conjunction with AZD5438, a potent inhibitor of cyclin-dependent kinase 2, produced synergistic protection against MIHL in the zebrafish model. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the Invention: Methods for the Prevention and Treatment of Hearing Loss.

[0001] Statement regarding federally sponsored research or development: This work was supported in part by NIHRQ1 DC015010, NIHR01 DGD15444,USAMRMCRH17003Q / 2QD079, ONR-N00014-18-1 -2507. The government has certain rights in the invention.Background of the invention:Field of the invention:

[0002] The present invention relates to therapeutic uses of active agent such as for treating, inhibiting, and / or preventing hearing loss.Description of related art including information disclosed under 37 .CFR 1.97 and 37 CFR 1.98:Over 35 million Americans suffer from hearing loss. In mammals, hair cell loss is permanent Noise-induced hearing loss (NIHL) affects a quarter of adult humans, many with work obligations in loud environments. The spiral-shaped cochlea of the inner ear is responsible for detecting sound. Inner hair cells lining the cochlea transform the mechanical vibrations of sound waves into chemical signals. These chemicals are then released from the hair cells and received by receptors on the auditory nerve fibers that send electrical impulses to the brain. The junction between a hair cell and a nerve fiber is called a synapse. Loud noise can release too much glutamate, overwhelming the receptors, which leads to loss of synapses and, eventually, a condition called sensorineural hearing loss. Currently, there are no clinically proven medications for the treatment of hearing loss (sensorineural and neural), or tinnitus associated with the inner ear, and a medication that could be used to prevent, alleviate, or eliminate hearing loss (or tinnitus) would thus be very desirable. The most common remedy for individuals suffering from severe sensorineural hearing loss is a hearing aid, which functions to amplify sound. Hearing aids are non-invasive and can improve an individual's ability to hear. However, hearing aids can often be quite conspicuous and embarrassing to the wearer and hearing aids do not return hearing to normal levels. Furthermore, hearing aids amplify sound indiscriminately, sometimes amplifying soundsthat an individual does not wish to hear, such as environmental noise. There exists a need in the art to provide otoprotective compounds that can be used to prevent hearing less due to noise, aging or drug treatment such as aminoglycoside antibiotics, macrolide antibiotics, salicylates, chemotherapeutic agents such as cisplatin, loop diuretics, antimaiariais, non-steroidal anti-inflammatory drugs (NSAIDs), quinine, and acetaminophen.Brief Summary of the Invention:

[0003] The inventive subject matter includes a method of protecting ear cells from death caused by an ototoxic event. This method includes the step of administering to an animal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Zorifertinib, or a pharmaceutically acceptable salt thereof. An ototoxic event includes drug treatments such as aminoglycoside antibiotics, macrolide antibiotics, salicylates, chemotherapeutic agents such as cisplatin, loop diuretics, antimaiariais, non-steroidal anti-inflammatory drugs (NSAIDs), quinine, and acetaminophen and noise.

[0004] The invention provides a method of protecting the ear cells from death caused by noise comprising administering to an animal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Zorifertinib, or a pharmaceutically acceptable salt thereof. In particular, the inventive subject matter relates to effective protection from noise that affects the high-frequency cochlear region of an ear. Additionally, the inventive subject matter includes providing a synergistic amount of AZD 5438.

[0006] Another inventive aspect includes: use of a composition AZD 5438 or AZD 3759 or a synergistic combination thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic and / or prophylactic treatment of hearing loss caused by an ototoxic event, such as noise or drug treatment such as aminoglycoside antibiotics, macrolide antibiotics, salicylates, chemotherapeutic agents such as cisplatin, loop diuretics, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), quinine, and acetaminophen. Use of a composition made of a synergistic combination a CDK2 inhibitor and an EGFR inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic and / or prophylactic treatment of hearing loss caused by an ototoxic event. Use of a composition comprising a Zorifertinib ( AZD 3759) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic and / or prophylactictreatment of hearing toss caused by an ototoxic event wherein the ototoxic event is noise exposure,

[0006] Another inventive aspect includes a kit comprising: an active agent, wherein the active agent is selected from the group consisting of AZD 5438 or AZD 3759 or a pharmaceutical acceptabie sait thereof: and one or more of:(A) at toast on© antibiotic;(B) at feast one cancer drug; and(C) instructions for preventing a hearing impairmentBrief description of the several views of the drawing:

[0007] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee, The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the invention. There are presently shown in the drawings embodiments which are presently preferred, it being understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown,

[0008] FIG. 1A shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0009] FIG. 1B shows an EGFR inhibitor that protects against hair ceil excitotoxicity in zebrafish.

[0010] FIG. 1C shows an EGFR inhibitor that protects against hair ceil excitotoxicity in zebrafish.

[0011] FIG. 1D shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0012] FIG. 1E shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0013] FIG. 1F shows an EGFR inhibitor that protects against hair call excitotoxicity in zebrafish.

[0014] FIG. 1G shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0015] FIG. 1H shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0016] Fl.G. 11 shows an EGFR inhibitor that protects against hair cell excitot oxi city in zebrafish.

[0017] FIG. 1J shows an EGFR inhibitor that protects against hair cell exci tot oxi city in zebrafish.

[0018] FIG. 1K shows an EGFR inhibitor that protects against hair cell excitotoxicity in zebrafish.

[0019] FIG. SA shows afatinib and zorifertinib protecting against noise-induced hearing ioss in mice.

[0020] FIG. 28 shows afatinib and zorifertinib protecting against noise-induced hearing loss in mice.

[0021] FIG. 2C shows afatinib and zorifertinib protecting against noise-induced hearing loss in mice.

[0022] FIG. 2D shows afatinib and zorifertinib protecting against noise-induced hearing loss in mice.

[0023] FIG. 2E shows afatinib and zorifertinib protecting against noise-induced hearing less in mice.

[0024] FIG. 2F shows afatinib and zorifertinib protecting against noise-induced hearing loss in mice.

[0028] FIGS. 3A shows afatinib and zorifertinib pretesting against cochlear synaptopathy in mice.

[0026] FIGS. 38 shows afatinib and zorifertinib protecting against cochlear synaptopathy in mice.

[0027] FIG. 4A shows conditional knockout of EGFR showing protection against flox / flox NIHL in mice. Baseline (pre-noise exposure) ABR thresholds of Pax2Cre; EGFR+ / + mice and Pax2Cre; EGFR control iittermates.

[0028] FIG. 4B shows no significant differences were detected between cKO and tiox / tioxWT. n-6-7. (8) Pax2Cre; EGFR mice (n=6) exhibited significantly smaller ABR threshold shifts (both 1-day (1 D) for TTS and 14-days (14D) for PTS) than wild-type (WT) littermate controls (Pax2Cre; EGFR+ +; n=6).

[0029] FIG. 4C shows ABR Wave- 1 amplitudes for 1@kHz stimulus respectively showed larger amplitudes at suprathreshold levels in the cKO compared to the WT but did not reach statistical significance. Two-way ANOVA, Holm-Sidak post hoc test, *****p<0.0001 , *** p=0.00Q7, black (1 D), magenta (14D). Data are presented as mean ± SEM.

[0030] FIG. SA shows EGFR signaling Is activated in the mouse cochlea following noise exposure and attenuated by zorifertinib.

[0031] FIG. SB shows EGFR signaling is activated in the mouse cochlea following noise exposure and attenuated by zorifertinib.

[0032] FIG. 5C shows EGFR signaling is activated in the mouse cochlea following noise exposure and attenuated by zorifertinib.

[0033] FIG. SD shows EGFR signaling activated in the mouse cochlea following noise exposure and attenuated by zorifertinib.

[0034] FIG.5E shows Zorifertinib suppresses noise-activated EGFR signaling pathways in mouse cochleae. (E) Heatmap of phosphorylation activity at the reporter peptides on the kinome panel (STK Pamchip; n=3 chips run in technical triplicate). Cochlear sensory epithelial lysates were collected 30-min post noise exposure from control, noise-exposed, zorifertinib-treated (Zori), and zorifertinib-treated plus noise- exposed (Zori_Noise) adult FVB mice. Each row represents a peptide. The protein kinase activity measured as phosphorylation of reported peptides on the chip is scaled with red being higher activity and yellow indicating lower activity.

[0035] FIG. 5F Log2-fold activity changes of reporter peptides “mapped" as putative targets of AKT and / or ERK kinase families (24 and 25 peptides, respectively) expressed as mean + / - standard deviation. Average of triplicates was used for each peptide per condition. N / C: Noise vs Control: Z / C: Zorifertinib vs Control; N+Z / C: Noise + Zorifertinib vs Control Bar: SEM; ****: P<0.0001 , ***: P<0.001 Two-way ANOVA.

[0036] FIG. G shews identification of specific protein kinases using complementary software packages (details in supplement). Selected AKT and ERK family members were identified as candidate “hits” using deconvolution strategies that specify protein kinases that are contributing to the phosphorylation signal seen across ail reporter peptides on the STK chip. Upstream Kinase Analysis (UKA), Post- translational Modification Signature Enrichment Analysis (PTM-SEA), and Kinase Enrichment Analysis 3 (KEA3) were used to identify specific kinases within the AKT and ERK families using online phosphosite mapping databases. Data were normalized and grouped as quartiles (1-4 black dots) for visualization using a bespoke Creedenzymatic R package.[0003T] FIG. 6 shows pharmacokinetics of orally delivered zorifertinib in mouse inner ear perilymph fluids, Measured concentrations of zorifertinib in mouse perilymph 0-6 has after oral gavage (15 mg / kg; n=3 / time point). Error bars indicate SEM. PK properties are calculated: T = 0.5h (Time of maximum perilymph concentration), T1 / 2- 2.1h (Half-life), Cmax= 99.9 62.6 ng / ml (Maximum concentration), AUC0-t= 189.9+ / - 48.3 ng / ml*h (Area under curve), Vz / F = 0.19 (Volume of distribution), Cl / F = 0.06 (mg / kg) / (ng / ml) / h (Clearance).

[0038] FIG. 7 shows synergistic otoprotection between zorifertinib and AZD5438 against excitotoxicity in zebrafish neuromasts. 5dpf zebrafish were pre-incubated with KA (5Q0pM) or regular fish water for 1 hour and then incubated for 2 hours with a combination of AZD5438 (CDK2 inhibitor) and zorifertinib (EGFR inhibitor) or with the individual compounds. Results are expressed as number of hair cells per neuromast ± SD. *P<Q.QS, **P<0.01 and ***P<0.001 versus KA alone (One-way ANOVA). A1 : AZD6438 50nM, A2: AZD5438 1nM, A3: AZD5438 10pM, Z1: Zorifertinlb 50nM, Z2: Zcrifertinib 1nM, Z3: Zorifertinlb 10pM.Detailed Description of the invention:

[0039] The present invention can be understood more readily by reference to the following detailed description of the invention and the examples included therein. Before the present compounds, compositions, articles, systems, devices, and / or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of case, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.

[0840] While aspects of the present invention can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present invention can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps areto be limited to a specific order, it is no way intended that an order be inferred, in any respect, This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification,

[0841] In one aspect, an active agent can be used as a therapy for the treatment and / or prevention of hearing loss. In various aspects, the compounds and compositions of the invention can be administered in pharmaceutical compositions, which are formulated according to the intended method of administration. The compounds of this invention are defined as a therapeutically active agent in a treatment regimen or procedure that is intended for preventing hearing toss by noise by protecting inner ear cells from death and in preventing hearing toss from noise. Therapeutic agent means a chemical substance that is used for the treatment or mitigation of a disease condition or ailment.

[0042] Materials:

[0043] Afatinib dimaieate was purchased from Cayman Chemical, USA. Zorifertinib (AZD3759) and AZD6438 were purchased from MedChemExpress, USA. Antibodies used included: C-terminal binding protein-2 (mouse anti-CtBP2; BD Transduction Labs, used at 1 :200), myosin-VIIA (rabbit anti-myosin-VHA; Proteus Biosciences, used at 1:250), anti-otoferlin (HCS-1 , DSHB 1 :600), anti-GFP (NB1 GO- 1614, Nevus Biologicals 1 :500), total AKT and EFK (Cell Signaling 9272S and 4695S, respectively), phospho forms (AKT-S473 and ERK1 / 2-T2Q2 / Y204, Cell Signaling) and p-actin (Sigma A3854).

[0044] Drug identification using LINCS Query:

[0045] Microarray and RNA-seq transcriptomes from cochlea following noise exposure that are available in the public Gene Expression Omnibus (GEO) database were analyzed using the National Center for Biotechnology Information (NCBI)’s GEO2R tool (https: / / www.ncbi. nlm.nih.gov / geo / geo2r / ) to identify differentially expressed genes between the two groups. Genes with an absolute log-fold change greater than 1 were downloaded from each study and analyzed with LINCS databases to identity compounds inducing similar gene expression profiles in various cell lines. The LINCS analysis relies on a subset of the 1 ,319,138 genetic profiles originally compiled in the L1000 compendium. For each profile, an overlap score between 0-1 was given, indicating the fractian of genes that either mimic or reverse the gene setinput. With over 100 identified compounds of interest, we further narrowed down the results of a screen by selecting those compounds with an overlap score >0.1 , indicating at least a 10% overlap between the small molecule perturbation from the databases and a gene expression profile.

[0046] Three comparison groups were created from the Gratton, et al. (M. A.Gratton et al., Noise-induced changes in gene expression in the cochleae of mice differing in their susceptibility to noise damage. Hear Res 277, 211-226 (2011).) DNA microarray data set. The first experimental group compared transcriptomes of the 129X1 / SvJ mouse without noise exposure to the B6.CAST mouse without noise exposure, this group served as a control group (N- / -) and identified DEGs that may have conferred resistance to NIHL in the 129X1 / SvJ mouse prior to noise exposure. The second experimental group compares the transcriptomes of the 129X1 / SvJ noise treated mouse to the 129X1 / SvJ control mouse and is referred to as (129 N+ / ~). The purpose of this group is to determine which genes may bo involved in hearing protection for the 129X1 / SvJ following noise exposure. The third experimental group compares the transcriptomes of the B6.CAST noise-treated mouse to B6.CAST control mouse and is referred to as (B6 N+ / -). The purpose of this group is to determine which genes may be involved in noise trauma ototoxicity after noise exposure.

[0047] 12,488 differentially expressed genes (DEGs) were identified for each of the three experiment groups using GEO2R and were ranked based on p-value and log- fold change. DEGs with a log fold change greater than 2 and p-value less than 0.05 were considered differentially expressed genes of interest. Using this threshold, 92 upregulated genes and 146 downregulated genes were found for the N-A group, 138 upregulated genes and 24 downregulated genes were found for the 129 N+A group, and 109 upregulated genes and 41 downregulated genes were found for the B6 N+A group. DEGs of interest were used for Gene Ontology pathway analysis using the ShinyGO enrichment analysis program (http: / / bioinformatics.sdstate.edu / go76 / ). This program identified 30 biological pathways for each experimental group. Pathways were ranked based on enrichment FDR value and the program identified which of the input genes were significant for each biological pathway.

[0048] L1000CDS2analyses were performed using the DEGs from each biological pathway with at least 3 upregulated and 3 downregulated DEGs of interest. Each L1D00GDS2analysis reveals 50 drug perturbations that mimic or reverse the input transcriptome and are ranked based on overlap score. In total, 65 L1000CDS2analyseswere performed; 27 analyses from the N- / - Mimic group. 13 analyses from the 129 N+ / - Mimic group, and 25 from the B8 N+ / - Reverse group. Therefore, 1 ,350 drug perturbations wore found that mimic the N- / - DEGs, @50 drug perturbations that mimic the 129 N+ / ~ DEGs, and 1 ,250 drug perturbations that reverse the B6 N+ / ~ DEGs. Drug perturbations with the highest overlap scores were considered significant and filtered the list of significant drug perturbations down to 189 significant drug perturbations from the NY- Mimic group, 53 significant drug perturbations from 129 N+ / - Mimic group, and 173 significant drug perturbations from the B6 N+ / - Reverse group. Drug perturbations were further filtered by targeting which drugs target multiple pathways. In total, 83 drug perturbations were found to target multiple pathways between the three experimental groups.

[0049] Two experimental groups were created from the Maeda st al. (Y. Maeda et al., immediate changes in transcription factors and synaptic transmission in the cochlea following acoustic trauma: a gene transcriptome study. Neurosci Res, (2020).) bulk RNA-seq data set. The transcriptcme of the C57B8 mouse without noise exposure was compared to the C57B6 mouse after noise exposure and identified 939 DEGs. DEGs with a log fold change greater than 2 were considered significant. Of the 939 DEGs, 51 significant upregulated genes and 222 significant downregulated genes were identified. In addition, the Maeda group examined significant DEGs that encode for transcription factors and identified 9 significant upregulated genes and 18 significant downregulated genes. The first experimental group used ail 51 upregulated genes and 222 downregulated genes as input to a L1000CDS2analysis. The second experimental group used the 9 upregulated genes and 16 downregulated genes that encode for transcription factors as input to a L1Q00CDS2analysis. The purpose of these two experiments was to identify drug perturbations that would reverse the transcriptome of the noise exposed C57B6 mouse. Each of these experiments identified 50 drug perturbations that were ranked based on overlap score for a total of 100 drug perturbations. Of these 100 drug perturbations identified, 43 drug perturbations of these were also identified from the Gratton et al. data set.

[0050] For the third dataset from Milon et al. (S. Milon et al, A cell-type-specific atlas of the inner ear transcriptional response to acoustic trauma. Cell Rep 30, 109758 (2021).), DEGs for outer hair cells and supporting cells (6 and 24 hours), marginal, intermediate, basal cells, fibrocytes from the cochlear lateral wall, and the spiral ganglion neurons were used as input for L1QQQCDS2queries. DEGs with a log foldchange greater than 1.2 were considered to be significant. For each cell type, the top 50 drugs ranted according tc the cosine distance scare were compiled. From the list of 500 drug perturbations, drugs, and mechanism of action classes were compared, and a consensus list was prepared for the three datasets.

[0051] Molecular docking:

[0052] Structure modeling, decking and analysis were done using the YASARA package (E. Krieger, G. Vriend, New ways to boost molecular dynamics simulations. J Comput Chem 36, 996-1007 (2015).). For docking dacomitinlb and zorifertinib tc the EGFR, the crystal structure of EGFR kinase afatinib complex was used (PDB id.4G5J). The missing residues 747-756 (LREATSPKAN) from the X-ray structure were inserted using the loop modeling option of YASARA. The completed structure was solvated with water molecules in a rectangular box so that the distance between protein and the box edge was 10 A. The structure of the solvated system was energy- minimized using the AMBER ff14SB force field (F. O. Kok et al. , Reverse genetic screening reveals poor correlation between morpholino-induoed and mutant phenotypes in zebrafish. Dev Ce / / 32, 97-108 (2015).) and then it was subjected ta 1 ns molecular dynamics (MD) simulation at 300 K temperature and 1 atm pressure. Using the last frame of the MD trajectory, afatinib was removed from the complex and the structures of dacomitinib and zorifertinib, obtained from https: / / pubchem.ncbi.nlm.nih.gov, were docked to the receptor using AutoDock VINA (O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461 (2010).) in YASARA. Molecular contact surface area and contact area color were determined by the ESPPBS method, which includes the implicit water effects.

[0053] Animals and drug administration:

[0054] Zebrafish: Danio rerio experimental larvae were obtained by pair mating of adult fish maintained at Creighton University by standard methods approved by the Institutional Animal Care and Use Committee. We used Tg(brn3c:mGFP) expressing a membrane bound GFP in HCs. Experimental fish were maintained at 28.5°C in E3 water (5 mM NaCI, 0.17 mM ClI, 0.33 mM GaCl2, and 0.33 nM MgSO4, pH 7.2). Animals were cryoanaesthetized after drug treatment and prior to fixation. The neuromasts inspected, SO3 and 01-2, were part of the cranial system.Mice: This study used 7 to W-week-old FVB / NJ mice obtained from The Jackson Laboratory (Bar Harber, ME, USA), with an equal number of males and females across the experiments. Conditional EGFR knockout mice were generated by crossing flexed EGFR mouse strain - (Egfrtm1Dwt(T.Q. Lee, D. W. Threadgill, Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis 47, B5-92 (2Q09).), Stock# Q31765-UNC, Mutant Mouse Resace and Research Center) with Pax2-Gre strain (92. T. Ohyama, A. K. Groves, Generation of Pax2~Cre mice by modification of a Pax2 bacterial artificial chromosome. Genesis 38, 195-199 (2004).). The mice were on mixed background (CD1 , CBA / CaJ, C57BL / 6).

[0055] Zebrafish drug studies:

[0056] The lateral line neuromasts of zebrafish are a valuable system for testing protectivity of compounds against cisplatin toxicity in vivo, as their HCs are considered homologous to those in the mammalian inner ear and are readily accessible to drugs.

[0057] To evaluate whether the drugs protect HCs from excitotoxic trauma, we employed a zebrafish model that mimics noise damage by exposing fish to the ionotropic glutamate receptor agonist, N-methyl-D-aspartate (NMDA) previously shown to cause progressive HC loss in zebrafish lateral-line organs. Briefly, 5-dpf larvae were preincubated with 300 pM NMDA for 50 minutes followed by 2 hours of incubation with the drugs at 0.002 pM and 0.0183 pM. [00O5S] Subsequently, animals were transferred to E3 water for 1 hour, fixed in4% paraformaldehyde (PEA) overnight and immunostained for otoferiin and GFP. HCs ware manually counted using a Zeiss AxioSkop 2 fluorescence microscope with a 40x oil objective. Compounds were then evaluated on efficiency and potency, with the top- rated compounds showing high protection at lower concentrations. For neuromast imaging, samples were analyzed under a Zeiss LSM 700 confocal microscope with an oil immersion objective of 63X (numerical aperture 1.4) and 1 ,3x digital zoom.

[0059] Noise exposure:FVB / NJ mice (6 to 7-weeks old) were exposed to noise inside a double-walled soundproof booth (IAC Acoustics). Awake mice held individually in small open-walled cylindrical containers inside a reverberant chamber were exposed to octave band noise (8-16 kHz at 1Q0 dB SPL) for 2 hours delivered via an exponential horn fitted on to a titanium horn driver (JBL 2426H) and driven by a power amplifier (Crown CDi1000) using RPvdsEx circuit and a RZ6 Multi-I / O processor (Tucker Davis Technologies, Alachua, FL). Before each session, the overall noise level was measured and calibratedat the center and fa quadrants of the reverberant chamber using a calibrated1 / 4" microphone (PCB 377C10). AH noise exposures were from noon to 2PM to minimize differences in circadian variation in sensitivity to noise. Noise exposure ievei was based on a previously published work (T. Teitz et al., CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 216, 1187-1203 (2018).) showing 8-16 kHz octave band noise at 100 dB for 2 hours causes 20 dB ABR threshold shift and IHC synaptic ribbon loss.

[0060] Auditory brainstem response (ABR):

[0061] Mice were anesthetized with avertin (5 mg / 10 g body weight, IP) and placed on a homeothermic heating pad in conjunction with a rectal temperature probe.Subcutaneous electrodes were inserted at the vertex (reference), posterior to the pinna (active), and ever the hip (ground). The acoustical stimulus generation, ABR wave acquisition, equipment control, and data management were performed using National Instruments PXI system with 6221 and 4461 modules and the EPL Cochlear Function Test Suite (CRTS). Stimuli were presented by a TDT QMF1 driver in an open field configuration placed 10 cm from the left ear of each animal. Tone-pip stimuli of 5 ms duration at half-octave frequency intervals from 4.8-64 kHz were presented at 21 / s. At each frequency, an intensity series was presented from 10-100 dB SPL in 5 dB incremental steps. 256 responses of alternating stimulus polarity were collected and averaged for each stimulus level. Evoked-response signal was amplified 10,008x (Grass P5-11 bio amplifier) and band pass filtered (Q.3-3 kHz) before digitization. ABR threshold was determined as the lowest stimulus level that produced a detectable ABR waveform (wave-1 to 5) that could be visualized. ABR threshold shifts were calculated by subtraction of the pre-exposure thresholds from the post-exposure thresholds.

[0062] Distortion product otoacoustic emissions (DPOAEs):

[0063] The primary tones f1 and f2 were generated end shaped using EPL CFTS software and Nl PXI system. The two primary tones were presented using two TDT MF1 speakers in closed field configurations. The primary tones were delivered using a custom probe insert attached to a low-noise ER10B+ microphone (Etymotic Research, USA). DPOAEs were recorded in the form of level / frequency functions; f2 / f1 was fixed at 1.2, with the level of the f2 (L2)1Q dB less than the f1 level (L1). The f2 stimuli were presented at 5.6 - 32 kHz at half-octave intervals. At each f2 frequency, L2 was varied between 65 and 5 dB SPL at 10 dB steps. The 2f1-f2 DPOAE amplitude and surrounding noise floor were extracted by offline analysis. DPOAE threshold wasdefined as the L1 level that produced emission at 2f1 -f2 with emission amplitude of 0 dB SPL. The average noise-floor was -25 dB SPL across frequencies.

[0064] Sample preparation and immunofluorescence labeling:

[0065] After the final ABR and DPOAE measurements, the mice were transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. After perfusion, cochleae were isolated and post-fixed in 4% PFA in Q.1 M phosphate buffer for 2 hours at room temperature. After fixation, the cochleae ware decalcified in 120 mlM EDTA far 2-3 days. Each cochlea was microdissected into three pieces and a cochlear frequency map was computed based on 3D reconstruction of the sensory epithelium for outer hair cells (OHCs) and presynaptic ribbon counts. Dissected pieces were permeabilized using 0.02 % Triton X-100 for 15 min, washed three times in PBS and preincubated for 1 hour in blocking buffer (10% normal goat serum) at room temperature. Cochlear pieces were incubated with CtBP2 or myosin-Vlla, with matching secondary antibodies (Alexa Fluor 488, 546; Life Technologies, USA). DAPI was used for nuclear staining (DAPI, Thermo Fisher, 1 :1000). Stained cochlear pieces were mounted on slides with Fluoromount-G medium (SeuthernBiotech, USA) and cover- slipped.

[0066] Quantification of synaptic ribbons:

[0067] Following the frequency map computation, cochlear structures were located to relevant frequency regions. Using a confocal microscope (Zeiss LSM 700), OHC and IHC zones were both imaged with a 63x, numerical aperture 1.4 with 1.0x digital zoom. For IHC ribbon synapse quantification, 3D (x-y-z-axis) images were scanned with the 1.3x digital zoom at 63x. Each immunostained presynaptic CtBP2 puncta was counted as a ribbon synapse. Synaptic ribbons of ten consecutive IHCs distributed within the 16-22 kHz frequency region were counted. The CtBP2 (presynaptic) puncta were counted using Imaris 9.5 (Oxford Instruments. Abingdon, UK) using the approach described by Fogarty et al. (M. J. Fogarty, L. A. Hammond, R. Kanjhan, M. C. Bellingham, P. G. Noakes, A method for the three-dimensional reconstruction of Neurobiotin-filled neurons and the location of their synaptic inputs. Front Neural Circuits 7, 153 (2013).). The average spot diameter was set to 0.45 pm, and only CtBP2 puncta found within the surface of the IHQ were included. The synaptic ribbons in the normal cochleae were also calculated using the same method to serve as control comparison samples.[009S8] Western blotting: For the immunoblot studies, animals were administered afatinib, zorifertinib er the vehicle 1 day before and immediately after the noise- exposure. Animals were sacrificed either 30 minutes after the noise-exposure and the cochleae isoiated and processed in lysis buffer (RIPA, ThermcFisher, 89901) containing protease inhibitors. Fifteen to thirty micrograms of protein were used for ths immunobiot experiments. Membranes were biocked with 3% miik blocking soiution and incubated with the primary antibodies overnight at 4°C. After several washes and the incubation with the secondary antibody, membranes were developed using a ChemiBlot system (Bio-Rad). Membranes were stripped and reprobed for the phosphorylated forms, β-actin was used as the loading control.

[90089] Kinome analyses: Identification of significant differential AKT and ERK family kinase activity: 24 AKT and 25 ERK kinase family putative target peptides were identified by the KRSA package (E. A. K. DePasquale el a / ., KRSA: An R package and R Shiny web application for an end-to-end upstream kinase analysis of kinome array data. PLoS One 18, ©0260440 (2021).). Log2-fold changes in peptide activity were calculated by comparing Noise, Zorifertinib, or Noise + Zorifertinib to control. For each peptide, an average of triplicates was used per condition. Two-way ANOVA was used to identify significant differences between groups (****: P<0.0001, ***: P<0.001), with results presented as mean ± standard deviation.

[80970] Methods Omnibus for the PamGene Kinome Array. Overview. ThePamGene platform is a well-established, highly cited, microarray technology for multiplex kinase activity profiling (R. Arsenault, P. Griebel, S. Napper, Peptide arrays for kinome analysis: new opportunities and remaining challenges. Proteomics 11. 4595- 4609 (2011). A. Baharanl, B. Trost, A. Kusalik, S. Napper, Technological advances for interrogating the human kinome. Biochemical Society Transactions 45, 65-77 (2017). E. Bentes et ai.. Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. Moi Qmics 15, 173-188 (2019). R. Hiihorst. L. Houkes, A. van den Berg, R. Ruijtenbeek, Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Analytical Biochemistry 357, 150-151 (2009).).

[0071] Hardware. Pamstation12 and PamChip4. The PamGene12 Kinome Array is a peptide array-based platform that facilitates the unbiased detection of kinase activity by serine / threonine (STK) or tyrosine (PTK) kinases (R. Arsenault, P. Griebel, S. Napper, Peptide arrays for kincme analysis: new opportunities and remainingchallenges, Proteomics 11, 4595-4609 (2011), A, Baharani, B. Trost, A, Kusalik. S, Napper, Technological advances for interrogating the human kinome. Biochemical Society Transactions 45, 65-77 (2017). E. Bentsa et al., Kinase network dysregulation in a human induced pluripotent stem cell model ef DISC1 schizophrenia, Mol Qmics 15, 173-188 (2019). R. Hilhorst, L. Houkes, A. van den Berg, R. Ruijtenbeek, Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Analytical Biochemistry 387, 150-161 (2009). J. L, McGuire et al., Abnormalities of signal transduction networks in chronic schizophrenia. NPJ Schizophr 3, 30 (2017). C. R. Dorsett et al. , Traumatic Brain Injury Induces Alterations in Cortical Glutamate Uptake without a Reduction inGlutamate Transporter-1 Protein Expression, J Neunctreuma 34, 220-234 (2017).). The STK and PTK PamGene12 chips have 144 and 196 reporter peptides, respectively. Each spot has approximately 300,000 copies of the same peptide printed on it. Phosphorylation is detected in real time. Fluorescent antibodies are applied against phosphorylated residues; fluorescent intensity is a proxy far the extent of reporter peptide phosphorylation. Altered kinase activity can be directly measured. For example, phosphorylation by PKA on the STK chip is concordant with its activity in solution (E. Bentea et al. , Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. Mol Omics 16, 173-188 (2019).). Each peptide chip has 4 wells, and three chips can be run at the same time. Thus, there are up to 12 samples for each “run” on the array,

[0072] Chip Coverage. Of the about 500 kinases in the human genome (G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, the protein kinase complement of the human genome. Science 288, 1912-1934 (2002)., G. Manning, Genomic overview of protein kinases. Worm Book : the online review of C. elegens biology, 1-19 (2005).), 245 / 378 (65%) Ser / Thr and 89 / 93 (96%) Tyr kinases can be mapped to the STK and PTK chips, respectively. The chips also map about 18 / 21 (86%) dual specificity kinases, covering about 72% of the entire kinome. The STK chip covers similar amounts of low (52%), medium (65%), and high (65%) abundance protein kinases in neurons (based on Brainseq neuron database (https: / / www.brainrnaseq.org / )) and has sensitivity for detection into the picogram range for many kinases.

[0073] Kinome Array Protocols, Date Generation. Samples are prepared according to the protocols provided by PamGene Corp (https: / / pamgene.com / ps12 / ).The catalytic activity and stability cf kinases are controlled by the addition of protease and phosphatase inhibitors. Peptide phosphorylation is monitored during the incubation with assay mixture, by taking images every 5 min for 60 min at exposure lengths of 5 msec, 25 msec and 100 msec, allowing real time recording cf the reaction kinetics. Various internal control tests have been performed by PamGene International to ensure the sensitivity of the assay. Chip-to~chip and run-to-run technical variation (coefficient of variability (CV)) is <9% and <15%, respectfully. Tc account far technical variation between runs, an internal control sample may be added tc account for between run variability.

[0074] Preliminary Data Processing. The primary output from PamStation12 is images from the Evolva kinetic image capture software. These images are then pre- processed to quantify the activity at each peptide level using the PamGene’s BioNavigator software (https: / / pamgena.com / wp-Before proceeding to activity analysis, all peptides that appear as inactive (Raw Signal 5) are removed from the analysis. The dynamic range of the raw signal intensities is typically 0 - 3,000. The linear regression slope of the signal intensity as a function of exposure time is used to represent the peptide phosphorylation intensity for downstream comparative analyses, averaged across the biological replicates. This is done to increase the dynamic range of the measurements. The signal ratio between case and control samples is used to calculate fold change (FC) values. Peptides with a fold change of at least 15% (i.e., FC > 1.15 or FC < 0.85) are considered differentially phosphorylated for the purposes of using KRSA. This threshold was chosen based on previous reports that suggest smell changes in kinase activity are sufficient to trigger biologically relevant changes (J. L. McGuire et al.. Abnormalities of signal transduction networks in chronic schizophrenia. NPJ Schizophr 3, 30 (2017)., C. R. Dorsett et al. , Traumatic Brain injury induces Alterations in Cortical Glutamate Uptake without a Reduction in Glutamate Transporter-1 Protein Expression. J Neurotrauma 34, 220-234 (2017)., J. A. Appuhamy et al. , Effects of AMP-activated protein kinase (ANIPK) signaling and essential amino acids on mammalian target of rapamycin (mTQR) signaling and protein synthesis rates in mammary cells. J Dairy Sci 37, 413-429 (2014).). Peptides that had a very low signal or an R2of less than Q.9Q during the corresponding linear regression are considered undetectable or non-linear in the post- wash phase and were excluded from subsequent analyses.

[0075] Assessment of Upstream Kinases. Peptides spotted an the array (and in general) may be phosphorylated by more than one kinase, and in many cases several different kinases. The use of two different types of chips, one for Ser / Thr kinases (STK) and one for Tyr kinases (STK) provides a starting point for assignment of kinases. There are 4 different software packages that may be depioyed for assignment of upstream kinases. All of them rely, to varying extents, on publicly available mapping databases. Each has strengths and weaknesses, some of which are discussed beiow.

[0076] Upstream Kinase Anaiysis (UKA). This package was developed by the Pamgene Corp (s’-Hertengobosch, Netherlands). UKA is integrated into the manufacturers BioNavigator software and their recommended method. This method relies on a curated database of kinase substrate interactions created by the PamGene Corp. It takes the raw output from the PamStation as input. It then filters low intensity peptides and scales the entire dataset to the range of 0-1 DD. It then calculates a “kinase Score” for each kinase and reports the ones with the highest score. Advantages include 1) providing results far specific kinases (as apposed to families) and 2) a low false positive rate compared to other packages.

[0077] Kinome Random Sampling Analyzer (KRSA). The package was developed by the Cognitive Disorders Research Laboratory (CDRL) at the College of Medicine and Life Sciences (COMLS) University of Toledo, led by Dr. Robert McCullumsmith (94 E. A. K. DePasquale et al., KRSA: An R package and R Shiny web application for an end-to-end upstream kinase anaiysis of kincme array data. PLoS One US, e0280440 (2021).). The data generated from the kinome array experiment and the mapping of the PamChip file are used as input to the algorithm. Once selected, peptides are filtered out using advancement criteria, including the signal intensity at maximum exposure time and the R2 values of the linear regression of signal intensity as a function of exposure time. At the end of this step, a list of filtered peptides moves forward to the next step of the analysis.

[0078] Curation of the database of upstream kinases. KRSA relies on a curated database of upstream kinases for the peptides present an the array. Protein kinases predicted to act on phosphorylation sites within the array peptide sequences were identified using GPS 3.0 and Kinexus Phosphonet (Kinexus Bioinformatics) (Y. Xue et al. GPS 2.1 : enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. Pratein Engineering Design end Seieetion 24, 255- 260 (2011)., C. Wang et al., GPS 5.0: An Update on the Prediction of Kinase-specificPhosphorylation Sites in Proteins. Genomics Proteomics Bioinformatios 18, 72-80 (2020)., Y. Xue et al. , GPS: a comprehensive www server for phosphorylation sites prediction. Nucleic Adds Research 33, W184-W187 (2005).). These programs provide predictions for serine-threonine kinases targeting peptide sequences ordered by likelihood of binding. The union of the highest ranked 5 kinases in Kinexus and kinases with scores more than two times the prediction threshold in GPS 3.0 were considered predicted kinases for each peptide and used in KRSA analysis (E. Bentea et ai., Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. Mol Omics 15, 173-188 (2019).). This list was combined with kinases shown in the literature to act on the phosphorylation sites of the peptides viaPhosphoELM (http: / / phospho.elm.eu.org) and PhosphoSite Pius (https: / / www.phosphosite.org).

[0073] Presentation of the data in KRSA[00O88] Heatmaps: Heatmaps are generated from the signal intensity data. The selection of peptides is based on the quality control criteria explained above. The values on ths heatmap are the slopes of the linear models of signal intensity as a function of the exposure time.

[8081] Violin Plots: Violin plots showcase the distribution of the signal intensity of significant peptides on a per-group basis.

[0082] Waterfall Plots: Waterfall plots are generated from the Z score values for each kinase. These values are generated on a chip-by-chip basis and then averaged across the three. The plot shows the distribution of these three points and a red dot showing the mean z score value.

[0083] Kinase Enrichment Analysis 3 (KEA3). KEA3 is an upstream kinase assignment method developed by the Maayan laboratory (https: / / maayanlab.cloud / kea3 / ) that relies on the known kinase protein interactions and kinase substrate interaction data and associated co-expression and co-occurrence data (M. V. Kuleshov et al., KEA3: improved kinase enrichment analysis via data integration. Nucleic Adds Res 49, W304-W316 (2021).). The KEA3 web server takes a set of phosphorylated proteins and their fold-change value as input and returns the putative upstream kinases using the database and looking for statistically significant over representation of kinases.

[0084] PTM Signature Enrichment Analysis (PTM-SEA). PTM-SEA (K. Krug e / a / ., A Curated Resace for Phosphosite-specific Signature Analysis. Moi Cell Proteomics18, 576-593 (2019)., J. Cox, M. Mann, MaxQuant enables high peptide identification rates, individualized p.p.b. -range mass accuracies and protecme-wide protein quantification. Nat Bioteahnol 26, 1367-1372 (2008).) is an application developed by the Broad Institute to identify putative upstream kinases. PTM-SEA is a modified form of the single sample Gene Set Enrichment Analysis (ssGSEA) with the underlying database built an top of PTMSigDB (K. Krug ef at., A Curated Resace for Phosphosite- specific Signature Analysis. Mat Co / / Proteomics 18, 576-593 (2019).). The software runs on the R Programming language. It takes in files in the Gene Cluster Text format which has the peptides and log fold change values in a specified format. The output from PTM-SEA is a list of putative upstream kinases that can phosphorylate each site.

[0085] integration of Upstream Kinase Assignments Across Packages. Ail the tools above utilize different methods to assign upstream kinases. This necessitates the use of en integration system to identify consensus upstream kinases across datasets. For this purpose, we utilize the software Creedenzymetic (Khaled, A. S. Imami, J. Creeden. (Zenodo, 2022).). The Creedenzymatic analysis takes in the results from at least two of the 4 analyses mentioned above and then generates a consensus figure with kinases deconvolved and ranked based on their presence in the results.

[0088] Perilymph sampling and quantitative mass spectrometry.

[8087] FVB mice (6-8 weeks old) were administered zorifertinib (15 mg / kg) via oral gavage, inner ear perilymph fluid was collected before and after (36 min, 1 hour, 2 hours, 4 hours, and 6 hours) the drug treatment. 1 pl samples were collected from the posterior-most, extracranial portion of the posterior semi-circular canal (K. Hirosa, J. J. Hartsock, S. Johnson, P. Santi. A. N. Salt, Systemic lipopolysaccharide compromises the blood-labyrinth barrier and increases entry af serum fluorescein into the perilymph. J Assoc Res Otolaryngol 15, 707-719 (2014).) and diluted 50-foid with 0.1% formic acid in water. Samples were frozen for later analysis and quantified via a LC-MS / MS in the Mass Spectrometry Core. Mice with vehicle treatment only were used as negative controls. Samples were spiked with a standard amount of 1 μg / ml IS (crizotinib). 20 μl of the diluted sample were injected in a Vanquish UPLC through a Waters Acquity BEH 18C 1.7 μm x 2.1 pm x 50 mm column coupled to a Q-exactive quadrupole mass spectrometer with eiectrospray ionization (ESI) interface. The column was maintained at 40°C. The mobile phase consisted of eluent A (0.1% formic acid in water) and eluent B (acetonitrile) at a flow rate of 0.2 ml / min with the following gradient: 0 to 1 mins - 6%B; 1 to 4 mins - 40%B; 4 to 6 mins - 50%B;.6 to 8 mins - 65%B, 8 to 16 mins100%B; 10 to 22 mins - 5%B. ESI conditions were: spray voltage - 3.9 kV; Capillary temp. 320°C. The PRM inclusion list was 460.153 (zarifertinib) and 450.13 (IS), and detection was run in positive pc. All acquisition and analysis of data was dene using Xcalibur software (Thermo Fisher Scientific, MA, USA).

[0088] Statistical analysis. All statistical analyses and graphical visualization were performed in GraphPad Prism v9.x (GraphPad, MA, USA). Comparisons between the treatment groups for A3R and DPOAEs were performed using two-way ANOVA followed by Holm-Sidak post hoc test. A paired student’s t-test was used for comparison of the CtBP2 puncta between experimental groups. ABR / DPOAE thresholds, and CtBP2 puncta counts were determined by an independent observer who was blinded to the treatment condition. For zebrafish quantification studies one- way ANOVA was performed followed by Dunnet post-hoc test. Statistical significance was set at p-value ≤0.05. Unless stated otherwise, the results are expressed as mean ± SEM.

[0089] Example 1 : EGFR inhibitors protect against hair cell excitotoxicity in zebrafish.

[0090] The efficacy of five EGFR inhibitors (afatinib, zorifertinib, osimertinib, JCN037, and dacomitinib) to protect against kainic acid (KA)-induced excitotoxicity in zebrafish lateral line neuromast model was evaluated as fallows. HG.1A: Osimertinib, FIG.1 B: JCNQ37, FIG.1C: Dacomitinib, FIG. D: Afatinib, FIG.1 E: Zorifertinib.

[0091] The number of hair cells is expressed as mean + / - SEM. *P<Q.Q5, ***P<0.001 versus KA-alone. One-way ANOVA. 1 F-1 K: Zebrafish non- injected or injected with 2ng of scrambled or EGF ligand (EGFL) specific morpholines (Gene Tools). Animals (3dpf) were pre-incubated with 500 mM of NMDA FIG. 1F, or KA FIG. 1G for 1 hour fallowed by 2 hours incubation with vehicle cr afatinib (1 pM). NMDA and KA incubations were used to mimic noise exposure (M. A. Grattan et al. , Naise- induced changes in gene expression in the cochleae of mice differing in their susceptibility to noise damage. Hear Res 277, 211-226 (2011).). Quantification af the HCs was performed in SO3, 01 and 02 neuromasts. **P<0.01, ***P<0.001 versus atotoxin alane. Φ P<0.05,0<0.D1 , ΦΦΦ P<0.001 versus the corresponding control(One-way ANOVA). FIG.1 H shows Zebrafish EGFL KDs incubated with KA (500 mM) followed by different concentrations of Zorifertinib. ***P<Q.Q1 versus KA alone (One- way ANOVA). I: Representative images of scrambled and EGFL marphants with the different treatments. GFP in green denotes the neuromast hair cells. Ctrl: control, KA:Kainic add incubation, KA+Afa 1mM: Kainic add and afatinib incubations, Afa 1mM: afatinib-only incubation. Vehicle treated EGFL morphants did not show any significant differences compared to non-injected or scrambled controls. FIG. 1J shows confirmation of EGFL knockdown by RT-PGR of scrambled and EGFL morphants. FIG. 1K shows hair cell quantification in the different morphants under baseline conditions (no excitotoxicity). Hair cell quantification is expressed as mean ± SEM.

[0092] Five-to-six days post fertilization (dpf) Tg (bm3o:GFP) zebrafish larvae were used far the assay. Fish were incubated with 500 mM of KA for one hour followed by various concentrations of the different EGER inhibitors (FIGS. 1A-1E). Except for JCN037 (FIG. 1B), all the EGFR inhibitors were protective at more than one concentration. To provide evidence that EGFR inhibitors act through the EGFR signaling pathway, we knocked down (KD) the EGF ligand (EGFL) in zebrafish (FIG.1J) and tested protection against N-methyl~D~aspartate (NMDA) FIG.1F) and KA (FIGS. 1G-11). As expected, the incubation of the EGFL knockdown animals with the EFGR inhibitors did not confer protection against excitotoxic damage (FIGS. 1F-1I), suggesting that the protective effect is mediated via EGFR pathway and that EGFR is the major pathway by which afatinib and zorifertinib protect against excitotoxicity. The use of two different EGFR inhibitors in combination with EGFL KD strongly points to the involvement of EGFR signaling cascade during hair cell excitctoxicity. To be noted, there were no differences in the number of neuromas hair cells between non-injected, scrambled-injected, and EGFL-injected animals, confirming the lack of morpholino off- target effect (FIG. 1K). Five-tc-six-days post-fertilization zebrafish were incubated with 500 mM of KA for 1 hour followed by two hours incubation with different concentrations of EGFR inhibitors. [000 93] Example 2: Afatinib and zorifertinib protect against noise-induced hearing loss in mice. Adult FVB mice (4-7 weeks old) were exposed to noise trauma (8-18kHz noise band at 100 dB SPL for 2 hours) indicated by the shaded box in the figures. A permanent threshold shift (PTS) FVB mouse model (T. Teitz &t al., CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 218, 1187-1203 (2018).) was used to evaluate the otoprotective effect. After baseline auditory function evaluation using auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) measurements, mice were exposed to 100 dB SPL 8-16 kHz octave band noise for 2 hours. Experimental animals were given either afatinib (20 mg / kg IP delivery) or zorifertinib (15 mg / kg oral delivery) one day before thenoise exposure and then continued for the following 4 days. Treatment with afatinib or zorifertinib significantly attenuated permanent threshold shifts (PTS) 14 days pest-noise exposure compared to the vehicle treated group (FIG, 2A-2D). Drug only treated animals did not show any significant difference in the threshold shifts. ABR threshold shifts were significantly attenuated at 16. 22.6, 32, 45.2 and 84 kHz frequencies for both drug treatment groups (FIG. 2A & 2C). DPOAE threshold shifts were most prominently protected in afatinib treated animals at 22.6 kHz (FIG. 2B). Although zorifertinib treated animals also showed lower DPOAE threshold shifts compared to the vehicle treated group, it did not reach statistical significance (FIG. 2D). In addition, significant differences were observed at multiple stimulus levels in ABR wave 1 amplitude input-output function at both 16 and 22.6 kHz frequencies in the afatinib treated group (FIG. 2E A 2F).

[0004] FIG, 2A shows ABR threshold shifts 2 weeks after the noise-exposure. Animals treated with 4 doses of afatinib 26 mg / kg / day IP showed significant difference in the threshold shifts at all tested frequencies when compared to those treated with the vehicle.

[0095] FIG. 2B shows DPOAE thresholds (a function of the outer hair cells of the cochlea; defined as the lowest level of f2 that produced an emission amplitude of 0 dB SPL and was also 6 dB higher than the corresponding noise floor). A significant difference in threshold were observed at 22.6kHz (p-0 0005).

[0096] FIG. 2C shows ABR threshold shifts 2 weeks after noise-exposure. Animals treated with 5 doses of zorifertinib 15mg / kg oral gavage showed significant protection at all tested frequencies above 16kHz (8,16 and 22 kHz p<0.00O1 ;32kHz p-0.0011 , 45.2kHz p=0.0447 and 64kHz p~0.0112).

[0097] FIG. 2D shows DPOAE threshold difference did not reach statistical significance.

[0096] FIGS, 2E & 2F show ABR Wave-1 amplitudes for 16kHz and 22 kHz stimulus respectively showing significantly larger amplitudes at suprathreshold levels in the afatinib treated animals compared to the vehicle treated (p=D.0085 - 0.0498 for afatinib and p-0.0233 - 0.Q352 at 80-90 dB SPL for zorifertinib). Two-way ANOVA, Holm-Sidak post hoc test. Data are presented as mean ± SEM, n=4-6 / group. Otoprotective effects of afatinib and zorifertinib were further evaluated in a mouse model of acute NIHL.

[0990] Example 3. Afatinib and zorifertinib protect against cochlear synaptopathy in mice. Now referring to FIGS, 3A-3B, in ths acute NIHL mouse model, moderately loud noise exposure doesn’t cause hair cell loss but is associated with permanent loss of cochlear afferent synapses on the IHCs (T. Teitz of a / ., CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 216, 1187-1203 (2018)., S. G. Kujawa, ML C. Liberman, Adding insult to injury: cochlear nerve degeneration after "temporary" noise-induced hearing less. J Neurosd 29, 14077- 14085 (2009).,. L. D. Liberman, J. Suzuki, M. C. Liberman, Dynamics of cochlear synaptopathy after acoustic overexposure. J Assoc Res Otelaryogol 16, 205-219 (2015).). Therefore, we examined synaptic ribbons in the IHCs in the 16-22 kHz region of the cochlea. Without noise, we found no difference in the number of CtBP2 presynaptic puncta among the zorifertinib, afatinib, and age-matched control groups. However, after noise exposure, there were significantly more CtBP2 presynaptic puncta in the zorifertinib and afatinib treated groups compared to the control, suggesting zorifertinib and afatinib protect against noise-induced cochlear synaptopathy.[000100] FIG. 3A shows Afatinib and zorifertinib protect against noise-induced cochlear synaptopathy in mice. FIG. 3A shows representative maximum intensity projections of inner hair calls (IHCs) in the 16-22 kHz region of the cochlea following drug treatment and with (left) or without noise (right). Hair cells were labeled using myssin-Vlla, presynaptic puncta were labeled using CtBP2, and nuclei were counterstained with Hoechst.[000101] FIG. 38 shows Zorifertinib and Afatinib protect against noise-induced cochlear synaptopathy, resulting In less CtBP2 puncta loss with drug + noise than control + noise. The number of CtBP2 puncta per inner hair cell (IHC) is expressed as mean + / - SD; n=2-5 animals per group. Each dot (n) represents one animal and the average CtBP2 puncta across ten IHCs from two cochleae. *P<0.05. **P<0.01 ,Welch's ANOVA. Z: Zorifertinib; A: Afatinib; C: Control; N: Noise.[000102] Conditional knockout of EGFR protects against NIHL in mice. Referring to FIGS. 4A-4C, a conditional knockout (cKO) mouse strain of EGFR by crossing EGFR floxed mice with Pax2~Cre mice were created. The Pax2-Cre; EGFR cKO mice showed normal hearing thresholds and cochlear morphology as their wildtype littermates. To test whether the Pax2-Cre; EGFR cKO mice were protected against NIHL, we exposed the mice to 2 hours of 100 dB SPL 8-16 kHz octave band noise, like the noise exposure in the afatinib and zorifertinib treated groups. cKO mice displayed significantly smallerABR threshold shifts at 8. 16, 22.8 and 32 kHz frequencies on both 1 day and 14 days after the noise exposure compared to the wildtype littermate controls. Wave 1 amplitudes of ABRs at 16 kHz were larger but did not reach significance in the cKO mice. These results are similar to the protection against NIHL offered by pharmacological inhibition of EGFR signaling (afatinib and zorifertinib).[000103] FIG. 4A shows baseline (pre-noise exposure) ABR thresholds of flox / flox +,+Pax2Cre; EGFR mice and Pax2Cre; EGFR control littermates. No significant differences were detected between cKO and WT. n=6-7. flox / fiox[00G104] FIG. 48 shows Pax2Cre; EGFR mice (n=6) exhibited significantly smaller ABR threshold shifts (both 1~day (1 D) for TTS and 14~days (14D) for PTS) than 4- / + wild-type (WT) littermate controls (Pax2Cre: EGFR ; n=6) C). ABR Wave-1 amplitudes for 1@kHz stimulus respectively showed larger amplitudes at suprathreshold levels in the cKO compared to the WT but did not reach statistical significance. Two-way ANOVA. Holm-Sidak post hoc test, ***** p<0.0001 , *** p=0.0007. black (1D), magenta (14D). Data are presented as mean ± SEM.[000105] Example 3. EGFR signaling is activated in the mouse cochlea following noise exposure and attenuated by zorifertinib. To determine whether EGFR signaling is functional in the adult cochlea, we treated wild-type FVB mice with zorifertinib (oral gavage at 15 mg / kg / day) a day before and at 1 hour during noise trauma. We exposed the mice to noise trauma (1QQdB SPL 8-16 kHz for 2 hours) and performed immunoblot analysis for downstream signaling targets of EGFR on cochlear lysates collected 30 minutes after the noise trauma. We found that ERK and ART phosphorylation was induced 30 min after noise exposure, but significantly reduced by the drug treatments.[000106] As shown in FIG. SA-5D, Western blotting was performed on organ of Corti lysates from mice 30 min after exposure to noise trauma (8-18kHz noise band at 100 dB SPL for 2 hours) and pretreated with either the drug (zorifertinib 15 mg / kg oral) cr the vehicle (normal saline or methyl cellulose) one day before and 1 hour during the noise trauma to detect the phosphorylation status (p- phosphorylated vs t- total) of two downstream effectors of EGFR (ART and ERK). Zorifertinib pretreatment significantly decreased the noise induced increase of ART and ERK phosphorylation. (A and C) The sizes of bands are labeled in kD. C - untreated and un-exposed control; V+N -vehicle + Noise; Z+N - zorifertinib + Noise; Z - zorifertinib only. Actin: a loading control. (B and D) Ratios of phosphorylated vs total proteins normalized to actin loading controls. Dataare normalized to untreated / exposed control mice as a ratio of 1 and presented as mean ± SD. N = 4-5 biological replicates and each dot represents ene mouse in each group. ANOVA, Tukey's post hoc. * p≤0.05, ** p≤0.01.[000107 ] Results corroborate with previous publications on noise induced activation of ERK and AKT pathways in similar post-exposure time points (Y. Maeda, K. Fukushima, R. Omichi, S. Kariya, K. Nishizaki, Time cases of changes in phospho- and total- MAP kinases in the cochlea after intense noise exposure. PLoS One 8, e58775 (2013)., I. Meltser, Y. Tahera, B. Canion, Differential activation of mitogen-activated protein kinases and brain-derived neurotrophic factor after temporary or permanent damage to a sensory system. Neuroscience 165, 1439-1446 (2010)., O. Selivanova, J. Brieger, U. R. Heinrich, W. Mann, Akt and c-Jun N-terminal kinase are regulated in response to moderate noise exposure in the cochlea of guinea pigs. ORL J Otorhinalaryngol Relat Spec 69, 277-282 (2007).. S. Jamesdaniel et at,, Noise induced changes in the expression of p38 / MAPK signaling proteins in the sensory epithelium of the inner ear. J Proteomics 75, 410-424 (2011).). Together, these results strongly indicate that EGFR signaling is functional and responsive to noise exposure. Most importantly, EGFR inhibitors are effective in mitigating the noise-induced activation of AKT / ERK signaling pathways in the adult mouse cochlea in vivo. Tc further elucidate the mechanisms of action by zorifertinib against noise trauma in the adult mouse cochlea, we used a novel kincme array to compare kinase signaling pathways in the cochlear lysates in mice treated with zorifertinib and / or noise trauma (see Methods). Specifically, a serine / threonine kinase (STK) Pamchip containing 144 immobilized peptides which were used as a readout of kinase activity. The arrays are spotted with reporter peptides, including controls, coupled to an activated aluminum oxide surface to create a 3-D structure facilitating interactions. During an experiment, the array is incubated with lysates of cells or tissue. The active kinases in the sample will phosphorylate their target on the array. Generic fluorescent labeled antibodies that recognize phosphorylated residues are used to visualize the phosphorylation in real time. [000108] Now referring to FIG.5E, Adult FVB mice were treated with zorifertinib(oral gavage at 15 mg / kg / day one day prior and 1 hour during noise trauma), exposed to noise (100 dB SPL 8-16 kHz for 2 hours), and cochlear lysates collected 30 min post- noise exposure, in conditions identical to Western blot analysis. We found that technical triplicates of each condition were highly reproducible.[000109] Now referring to FIG.5F zorifertinib suppressed multiple signaling pathways, and signaling downstream of EFGR was higher in noise exposed conditions but treatment with zorifertinib suppressed noise-induced activation of AKT / ERK signaling activities 30-min post-noise exposure. Using various deconvolution strategies (Upstream Kinase Analysis [UKA], Post-translational Modification Signature Enrichment Analysis [PTM-SEA], and Kinase Enrichment Analysis 3 [KEA3]; see Methods), wo identified selected AKT and ERK family members as candidate “hits” that are contributing to the phosphorylation signal seen across all reporter peptides on the STK chip (FIG. 5G). These results are consistent with a Western results (FIG, 5A-5D) and previous publications under similar conditions, thus confirming that inhibition of the EGFR signaling pathway is a mechanism of action by zorifertinib against NIHL in the adult mouse cochlea.[000119] EGFR signaling is activated in the mouse cochlea following noise exposure and attenuated by zorifertinib, (SA-SD) Western blotting was performed on organ of Corti lysates from mice 30 min after exposure to noise trauma (8-16kHz noise band at 100 dB SPL for 2 hours) and pretreated with either the drug (zorifertinib 15 mg / kg oral) or the vehicle (normal saline or methyl cellulose) one day before and 1 hour during the noise trauma to detect the phosphorylation status (p- phosphorylated vs t- total) of two downstream effectors of EGFR (AKT and ERK). Zorifertinib pretreatment significantly decreased the noise induced increase of AKT and ERK phosphorylation. (A and C) The sizes of bands are labeled in kD. C - untreated and un-exposed control; V+N -vehicle + Noise; Z+N - zorifertinib + Noise: Z - zorifertinib only. Actin: a loading control (B and D) Ratios of phosphorylated vs total proteins normalized to actin loading controls. Data are normalized to untreated / exposed control mice as a ratio of 1 and presented as mean + SD. N - 4-5 biological replicates and each dot represents one mouse in each group. ANOVA, Tukey's pest hoc.*p≤0.05, ** p≤0.01. (SE-SG) Zorifertinib suppresses noise-activated EGFR signaling pathways in mouse cochleae. FIG, 5E shows an aglqbeatmap of phosphorylation activity at the reporter peptides on the kinome panel (STK Pamchip; n~3 chips run in technical triplicate). Cochlear sensory epithelial lysates were collected 30-min pest noise exposure from control, noise-exposed, zorlfertinib-treated (Zori), and zorifertinib-treated plus noise-exposed (Zori-Noise) adult FVB mice. Each row represents a peptide. The protein kinase activity measured as phosphorylation of reported peptides on the chip is scaled with red being higher activity and yellow indicating lower activity. (5F) Log2~fold activity changes ofreporter peptides “mapped” as putative targets of AKT and / or ERK kinase families (24 and 25 peptides, respectively) expressed as mean + / - standard deviation. Average of triplicates was used for each peptide per condition. N / C: Noise vs Control; Z / C: Zorifertinib vs Control; N+Z / C: Noise + Zorifertinib vs Control. Bar: SEM; ****: P<0.0001, ***: P<0.001 Two-way ANOVA. FIG. 5G shows identification ef specific protein kinases using complementary software packages (details in supplement). Selected AKT and ERK family members were identified as candidate “hits” using deconvolution strategies that specify protein kinases that are contributing to the phosphorylation signal seen across all reporter peptides on the STK chip. Upstream Kinase Analysis (UKA), Post-translational Modification Signature Enrichment Analysis (PTM-SEA), and Kinase Enrichment Analysis 3 (KEA3) were used to identify specific kinases within the AKT and ERK families using online phosphosite mapping databases. Data were normalized and grouped as quartiles (1 ~4 black dots) for visualization using a bespoke Creedenzymatic R package. [000111] Now referring to FIGS. 0-7 to validate orally delivered zorifertinib crosses the blood labyrinth barrier (BLB) of the inner ear, we performed perilymph collection of adult FVB mice at various time points after oral gavage of zorifertinib (15 mg / kg). To accurately measure the perilymph concentration of zorifertinib, we performed LQ- MS / MS measurement of zorifertinib in ~ 1uL perilymph fluid collected from each mouse using crizotinib as an internal standard (IS); the calibration curve showed linearity within the measured range, with a lower limit of quantification (LLOQ) of 5 ng / ml. (A~8) MS2 spectra of Zorifertinib (A) and IS- Crizotinib (B). (C) Sample chromatogram showing peaks for both zorifertinib (right) and IS (left). (D) Calibration curve linear regression. The time case of zorifertinib concentrations in perilymph is shown in FIG, 7. The Cmax was 100 ng / mi and tmax was 30 min after oral gavage, while tvs was ~130 min and zorifertinib was cleared from perilymph in 6 hours. These PK results in the inner ear fluids are consistent with protection of zorifertinib we observed in mice with noise exposure.[000112] Now referring to FIG 7, Zorifertinib shows synergistic effects with CDK2 inhibitor AZD5438 in zebrafish. Given the multiple pathways involved in pathophysiology of NIHL, we hypothesized that the EGFR inhibitor could synergize with an inhibitor of ths CDK2 pathway and thus increase the levels of protection against NIHL. For this purpose, we used the zebrafish model for glutamate excitotoxicity to test the protective effect of zorifertinib in the presence of AZD5438, a CDK2 inhibitor that wehave characterized before as an otoprotective compound against NIHL (M. A. Ingersoll et al. , BRAF inhibition protects against hearing loss in mice. Sc / Adv S, (2020),). Zebrafish larvae were pre-incubated with 500 μM kainic acid or controi fish water for 1 hour followed by incubation with a combination of varying doses of zorifertinib and AZD5438. Dose combinations of zorifertinib (1nM) + AZD5438 (50nM ), zorifertinib(50nM) * AZD5438 (1nM) and zorifertinib (50nM) + AZDS438 (50nM) showed synergistic protection compared to treatment with the individual drugs. These results demonstrate that zorifertinib and the CDK2 inhibitor, AZD5438, act in synergy against NIHL via inhibiting both EGFR and CDK2 signaling pathways. 5dpf zebrafish were pre- incubated with KA (500μM) or regular fish water for 1 hour and then incubated for 2 hours with a combination of AZD5438 (CDK2 inhibitor) and zorifertinib (EGFR inhibitor) or with the individual compounds. Results are expressed as number of hair cells per neuromast ± SD. *P<Q,Q5, **P<0,Q1 and ***P<Q.QQ1 versus KA alone (One-way ANOVA). A1 : AZD5438 5DnM, A2: AZD5438 1nM, A3: AZD5438 10pM, Z1 : Zorifertinib 50nM, Z2: Zorifertinib 1 nM, Z3: Zorifertinib 10pM.[000113] Zorifertinib shewed excellent protection against glutamate excitotoxicity that mimics noise damage in the zebrafish lateral line neuromast model. Furthermore, we have shown that combinatorial treatment with EGFR inhibitors and a specific, potent CDK2 inhibitor AZD5438, synergistic otopratection is observed in the zebrafish model. We tested protection against NIHL using a permanent threshold shift noise exposure paradigm in a mouse model. Pretreatment with zorifertinib provided 20-30 dB of otopratection at all tested frequencies. Exposure to octave band noise produces maximum damage in cochlear regions that are 1.5 octaves higher. Significant otopratection was observed even in the 64 kHz regions which is in the high-frequency cochlear region. Zorifertinib displayed excellent pharmacokinetic properties that are desirable for CNS / BLB penetrating drugs.[000114] The compounds and compositions described herein can be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. For example, a pharmaceutical composition can be formulated for local or systemic administration, e.g., administration by drops or injection into the ear, insufflation (such as into the ear), intravenous, topical, or oral administration. Compounds can be synthesized by a variety of methods known in art.[000115] In one aspect, these compounds can be used as a therapy for the treatment and / or prevention of hearing loss. The invention is directed to non-age-related hearing loss such as tinnitus, sensorineural hearing toss, neural hearing toss, and Meniere’s disease. Mere specifically, sensorineural hearing toss includes noise related hearing loss which can be prevented or treated by administering to an animal in need thereof an effective amount of a pharmaceutical composition containing these compounds.[000116] The term "hearing toss" refers to a defect in the ability to perceive sound and includes partial hearing loss, complete hearing toss, deafness (complete or partial) , and tinnitus, the perception of non-existent sounds, i.e., a buzzing in the ear. The hearing toss may be due to hair cell or neuron damage, wherein the damage is caused by a genetic disorder, loud sounds, ototoxicity, or any other such stressor described in the application. Hearing toss includes sensorineural hearing loss, conductive hearing loss, combination hearing toss, mild (between 25 and 4Q dB). moderate (between 41 and 55 dB), moderately severe (between 56 and 70 dB), severe (between 71 and 90 dB), and profound (90 dB or greater) hearing loss, congenital hearing loss, pre-lingual and post-lingual hearing loss, unilateral (affecting one ear) and bilateral (affecting both ears) hearing toss, or any combination of these, i.e., sensorinoural / severe / postlingual / bilateral.[000117] to various aspects, the compounds and compositions of the invention can be administered in pharmaceutical compositions, which are formulated according to the intended method of administration. The compounds and compositions described herein can be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. For example, a pharmaceutical composition can be formulated for local or systemic administration, e.g., administration by drops or injection into the ear, insufflation (such as into the ear), intravenous, topical, or oral administration. Zorifertinib may be synthesized by methods known in the art.[000118] Zorifertinib is an otoprotective compound that can be used to prevent hearing toss due to noise, aging, Cisplatin, and antibiotic treatment by providing protection against the loss of hair cells. Zorifertinib is identified as acting against hair cell toss in animals by ths models and data presented. Models reveal that Zorifertinib protects against hair cell toss through interaction with EGFR. Zorifertinib is revealed to have high efficacy in mouse and zebrafish models used to demonstrate protection against hair cell toss. The lateral line neuromasts of zebrafish are a valuable model for testing compounds protective against cisplatin toxicity to w’vo, as their HCs areconsidered homologous to those in the mammalian inner ear and are readily accessible to drugs fo vivo. Teitz et al., J. Exp. Med. 2;215(4): 1187-1203 (2018). Mouse models measuring ABF? threshold shift to indicate hearing loss have previously been described. Teitz et al., J. Exp. Med. 2:215(4): 1187-1203 (2018). [000119] The nature of the pharmaceutical compositions for administration is dependent on the mode of administration and can readily be determined by one of ordinary skill in the art. In various aspects, the pharmaceutical composition is sterile or sterilizable. The therapeutic compositions featured in the invention can contain carriers or excipients, many of which are known to be skilled artisans. Excipients that can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, polypeptides (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, water, and glycerol. For example, administration can be parenteral, intravenous, subcutaneous, or oral. Methods for making such formulations are well known and can be found in, for example, Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA 1990.[000120] In various aspects, the disclosed pharmaceutical compositions include the disclosed compounds (including pharmaceutically acceptable sait(s) thereof) as an active ingredient, a pharmaceutically acceptable carrier, and, optionally, other therapeutic ingredients or adjuvants. The instant compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active agent is being administered. The pharmaceutical compositions can be presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.[000121] In various aspects, the pharmaceutical compositions of this invention can include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of the compounds cf the invention. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds. The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar,pectin, acacia, magnesium stearate, and stearic acid. Examples ef liquid carriers are sugar syrup, peanut oil, alive oil and water.[000122] In preparing the compositions for oral dosage farm, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs, and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules, and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques. A tablet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets can be prepared by compressing, in a suitable machine, the active agent in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.[000123] The pharmaceutical compositions of the present invention include a compound of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active agent is being administered. Pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.[000124] Pharmaceutical compositions of the present invention suitable for parenteral administration can be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in giyoerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.[000125] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, thecompositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In ell cases, the final injectable form must bo sterile and must be effectively fluid for easy syringability . The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.[000126] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above can include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of the invention, and / or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.[000127] A pharmaceutically effective amount is the dosage for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation, or allergic response. Although individual needs may vary, the determination of optimal ranges far effective amounts of formulations is within the skill of the art. Human doses can readily be extrapolated from animal studies (Katocs et al., (1990) Chapter 27 in Remington’s Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA), in general, the dosage required to provide an effective amount of a formulatian, which can be adjusted by one skilled in the art, will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies et al., (1996) Chapter 3, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY). [000128] The following are intended to be exemplary of how one of ordinary skill in the art could make and evaluate the claimed methods compounds, compositions, articles, and / or devices, and are not intended to limit the scope of the invention.

Claims

What is Claimed:

1. A method of protecting ear cells from death caused by an ototoxic event comprising administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Zorifertinib ( AZD 3759) , or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the ototoxic event is noise exposure.

3. The method of claim 2, wherein the noise is the human audible frequency range.

4. The method of claim 3, wherein the noise is detected in a high frequency region of the cochlea.

5. The method of claim 4, the high frequency region of the human cochlea is equivalent to at least 64 kHz in the mouse cochlea.

6. The method of claim 1 , comprising administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is further comprising a synergistic amount of AZD 5438.

7. The method of claim 1 , comprising administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is further comprising a synergistic amount of afatinib.

8. Use of a composition comprising a synergistic combination a CDK2 inhibitor and an EGFR inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic and / cr prophylactic treatment of hearing loss caused by an ototoxic event.

9. The method of claim 8, wherein the ototoxic event is noise exposure.

10. The method of claim 9, wherein the noise is the human audible frequency range.

11. The method of claim 10, wherein the noise is detected in a high frequency region of the cochlea.

12. The method of claim 11 , the high frequency region of the human cochlea is equivalent to at least 64 kHz in the mouse cochlea.

13. The method of claim 8, wherein the CDK2 inhibitor is AZD 5438.

14. The method of claim 8, wherein the EGFR inhibitor is Zorifertinib ( AZD 3759).

15. The method of claim 8, wherein the EGFR inhibitor is afatinib.

16. Use of a composition comprising a Zorifertinib ( AZD 3759) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic and / or prophylactic treatment of hearing loss caused by an ototoxic event wherein the ototoxic event is noise exposure.

17. The method of claim 16, wherein the noise is the human audible frequency range.

18. The method of claim 17, wherein the noise is detected in a high frequency region of the cochlea.

19. The method of claim 18, the high frequency region of the human cochlea is equivalent to at least 64 kHz in the mouse cochlea.

20. A kit comprising: an active agent, wherein the active agent is selected from the group consisting of AZD 5438 or AZD 3759 or a pharmaceutically acceptable salt thereof; and one or more of :at least one antibiotic; at least one cancer drug; and instructions for preventing a hearing impairment .